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Using Surveillance Data to Determine Treatment Rates
and Outcomes for Patients With Chronic Hepatitis C
Virus Infection
Sam Lattimore,1 Will Irving,2 Sarah Collins,1 Celia Penman,1 and Mary Ramsay,1 on Behalf of the
Collaboration for the Sentinel Surveillance of Blood-Borne Virus Testing
The aim of this work was to develop and validate an algorithm to monitor rates of, and
response to, treatment of patients infected with hepatitis C virus (HCV) across England
using routine laboratory HCV RNA testing data. HCV testing activity between January
2002 and December 2011 was extracted from the local laboratory information systems of a
sentinel network of 23 laboratories across England. An algorithm based on frequency of
HCV RNA testing within a defined time period was designed to identify treated patients.
Validation of the algorithm was undertaken for one center by comparison with treatment
data recorded in a clinical database managed by the Trent HCV Study Group. In total,
267,887 HCV RNA test results from 100,640 individuals were extracted. Of these, 78.9%
(79,360) tested positive for viral RNA, indicating an active infection, 20.8% (16,538) of
whom had a repeat pattern of HCV RNA testing suggestive of treatment monitoring.
Annual numbers of individuals treated increased rapidly from 468 in 2002 to 3,295 in
2009, but decreased to 3,110 in 2010. Approximately two thirds (63.3%; 10,468) of those
treated had results consistent with a sustained virological response, including 55.3% and
67.1% of those with a genotype 1 and non-1 virus, respectively. Validation against the Trent
clinical database demonstrated that the algorithm was 95% sensitive and 93% specific in
detecting treatment and 100% sensitive and 93% specific for detecting treatment outcome.
Conclusions: Laboratory testing activity, collected through a sentinel surveillance program,
has enabled the first country-wide analysis of treatment and response among HCV-infected
individuals. Our approach provides a sensitive, robust, and sustainable method for monitor-
ing service provision across England. (HEPATOLOGY 2014;59:1343-1350)
T
he Health Protection Agency (HPA) estimated
that, in 2005, approximately 203,000 hepatitis
C virus (HCV) antibody (Ab)-positive individ-
uals 15-59 years of age were living in England;
161,000 were chronically infected.1 Treating these
individuals represents a considerable challenge for the
National Health Service (NHS), not least because for
many, their infections remain undiagnosed. For those
diagnosed, antiviral treatments are available that will
successfully clear the virus in the majority of patients.
Those who are treated and achieve a sustained virolog-
ical response (SVR) will experience long-term disease
remission and liver-related mortality rates comparable
to the general population and are generally considered
“cured”.2-4 However, despite well-disseminated guide-
lines on the management and treatment of HCV, serv-
ice provision in England is variable, with low rates of
onward referral and treatment.5,6
Primary diagnosis of HCV in England relies on test-
ing for anti-HCV Ab, which, if positive, should be
routinely followed by testing for the presence of HCV
RNA, usually by polymerase chain reaction (PCR).
Genotyping should also be routinely perfumed to
guide treatment choice and is associated with treat-
ment outcome. In the UK, as in Europe and North
America, genotype 1 predominates,7-10 whereas geno-
type 4 is more prevalent in Africa and the Middle
East.11,12 Genotypes of individuals diagnosed within
the UK are therefore likely to reflect the countries
within which they acquired their infection.
Abbreviations: Ab, antibody; aOR, adjusted odds ratio; BASL, British Association for the Study of the Liver; CI, confidence interval; DAA, direct-acting antivi-
ral; HCV, hepatitis C virus; HPA, Health Protection Agency; NHS, National Health Service; PCR, polymerase chain reaction; SVR, sustained virological response;
NICE, National Institute for Health and Care Excellence; NPV, negative predictive value; Peg-IFN, pegylated interferon; PPV, positive predictive value; RBV, rib-
avirin; SVR, sustained virological response.
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Treatment regimens described in the 2006 guidelines
recommend a treatment duration of 48 weeks for those
with a genotype 1 virus and 24 weeks for those with a
genotype non-1 virus.13 For those who undergo treat-
ment, response is monitored through repeat HCV RNA
testing. Although frequency of HCV RNA testing varies
between centers, testing is usually undertaken at the out-
set of treatment, at 4 weeks for detection of a rapid viro-
logical response, at 12 weeks for detection of an early
virological response, if positive at 4 weeks, at the end of
treatment, and again 3-6 months after the end of treat-
ment to assess for SVR.13 Therefore, those on treatment
would be expected to have had a minimum of three
HCV RNA test results within 390 days of the treatment
start date (because treatment monitoring extends beyond
treatment administration), with additional HCV RNA
test results beyond this time frame for those with a geno-
type 1 infection and longer treatment duration.
Previous attempts by the HPA and the British Asso-
ciation for the Study of the Liver (BASL) to collect
national treatment data for HCV have been disap-
pointing.14 In 2012, the HPA used national data from
pharmaceutical companies, pharmacy purchasing data,
and pharmacy prescribing data to estimate the total
number of individuals who had been treated in Eng-
land.15 However, as new drugs for treating hepatitis C
are approved, these approaches are no longer valid and
new methods are required to estimate treatment rates.
As a result, there is currently no national surveillance
system in place through which it is possible to monitor
access to, and success of, treatment, without which the
impact and implementation of national HCV strat-
egies cannot be evaluated. The primary aim of this
study was to use routine laboratory testing data to
monitor the number of individuals undergoing pat-
terns of repeat HCV RNA testing suggestive of referral
and treatment and to thereby develop an easily appli-
cable tool to monitor treatment uptake at the individ-
ual level. A secondary aim of the study was to explore
the extent to which response to therapy could be
assessed over time.
Materials and Methods
Data collection methods have been described else-
where.16 In summary, demographic and testing data for
all individuals tested for anti-HCV Ab and HCV RNA
between January 2002 and December 2011 were
extracted from 23 participating laboratory information
systems in England. Individuals were identified using a
unique reference number and linked to all related test
results. Individuals were deduplicated, and test results
for each individual were linked over time using a combi-
nation of soundex of surname, first initial, date of birth,
and NHS number. Quality-control samples, children
less than 1 year of age (because a positive test for anti-
HCV in this group may be the result of passively
acquired maternal Abs) those without a positive HCV
RNA test result and individuals tested through renal
units were excluded from this analysis. Participating lab-
oratories are estimated to cover approximately 65% of
the English population for primary and reference HCV
testing and are broadly representative of most laborato-
ries providing routine and reference HCV testing.17
Information on each individual and all their associ-
ated tests were run through a suite of algorithms writ-
ten in the R statistical programming language on a
Linux platform. Individuals with active infection indi-
cated by a positive HCV RNA test result and three or
more sequential HCV RNA test results within a 390-
day period, suggestive of monitoring during treatment,
were identified. The year of the first HCV RNA test
result in this series was assumed to approximate to the
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year treatment was initiated. Results of qualitative and
quantitative HCV RNA test results were combined to
identify HCV RNA–positive individuals, and those
treatment-experienced individuals with a final negative
HCV RNA test result within the 390-window periods
were considered to have responded to therapy and
achieved an SVR. However, if an individual had a sub-
sequent positive HCV RNA test result, they were
reclassified as relapsed responders.
The algorithm was validated against treatment infor-
mation contained within the Trent HCV Study Group
database.6 This clinical database contains detailed infor-
mation of patients followed up longitudinally as part of
the Trent HCV cohort study based at Queens Medical
Center in Nottingham and includes patients referred to
one of the participating clinics in Derby, Leicester, Lin-
coln, Nottingham, and Sheffield. This cohort was estab-
lished in 1991 with the objective of studying the
epidemiology and natural history of HCV infection and
facilitating research into the pathogenesis of HCV-
associated disease. Laboratory testing information for
centers in Nottingham and Derby are routinely collected
through the sentinel surveillance system. Treatment
information recorded in the Trent study database was
compared to that inferred by patterns of repeat HCV
RNA testing. Identifiers included NHS number, date of
birth, and initials, all of which were used to match the
individuals to the sentinel surveillance system.
Statistical Analysis. Data were stored in Oracle
database (Oracle Corporation, 2001; Oracle9i Enter-
prise Edition Release; Redwood Sores, CA). Statistical
analyses were performed in the R statistical environ-
ment; trends analyzed using chi-squared test for trend,
and differences in ages were assessed using Wilcoxon’s
nonparametric test. The sensitivity and specificity of
the algorithm was estimated against the Trent study
database, and a Cohen’s kappa statistic was calculated.
Finally, multivariate logistic regression was performed
to determine factors independently and significantly
associated with being treated, and treatment response
was expressed as adjusted odds ratios (aORs) with
associated 95% confidence intervals (CIs).
Results
Individuals Treated in England. Between January
2002 and the end of December 2011, 267,887 HCV
RNA test results among 100,640 individuals were
received. Of these, 78.9% (79,360) tested positive for
viral RNA, indicating an active infection. Overall,
20.8% (16,538) of individuals with an active infection
had a repeat HCV RNA testing pattern suggestive of
treatment (Table 1); two thirds (65.6%; 10,842 of
16,538) of these were treated within 1 year of their
first HCV RNA test, increasing to three quarters
(74.1%; 12,250 of 16,538) within 2 years.
A significantly higher proportion of males were found
to have an active infection than females (81.0% vs.
72.8%; P< 0.001), and although there was no significant
difference in proportion treated by gender (P5 0.58),
the proportion treated was strongly associated with eth-
nicity, genotype, and age group (P< 0.001; Table 1).
Overall, individuals who were treated were older (Wil-
coxon, P< 0.001) than those who were not, although the
difference was small (median, 41 vs. 38 years).
The number of individuals with evidence of starting
antiviral therapy has increased significantly (P< 0.001)
since 2002 (Fig. 1), but declined between 2009 and
2010. When stratified by genotype, the increase in the
numbers treated between 2007 and 2009 was less pro-
nounced among those with a genotype 1 infection.
Overall, 63.3% (n5 10,468) of all individuals appa-
rently treated had a final negative HCV RNA test result
and were significantly younger than those without evi-
dence of response to treatment (Wilcoxon, P< 0.001;
median, 38 vs. 42). The odds of a treatment response
(adjusted for age group, sex, ethnicity, and genotype)
was significantly higher among females than males and
among those of Asian or Asian British ethnicity, com-
pared to those of white or white British ethnicity, and in
those with a non–genotype 1 infection. Rates of treat-
ment response varied by genotype, with 55.3% of those
with a genotype 1 virus and 58.5% of those with a geno-
type 4 virus responding to treatment, compared to
69.2% and 67.4% among those with a genotype 2 and
3 virus, respectively (Table 2).
Validation Against the Trent Clinical Database. The
validation exercise used information on 889 HCV-
positive individuals from the Trent clinical database
who had attended either the Nottingham or Derby
clinics. Overall, 711 (79.9%) individuals could be
matched to the sentinel laboratory database using a
combination of NHS number and date of birth. Of
these, 55 (7.7%) had a treatment start date preceding
the start of the sentinel surveillance system in 2002
and were excluded. Of the remaining 656 (93.3%),
198 (30.1%) did not match to an individual with a
HCV RNA test result in the sentinel surveillance data-
base and therefore could not be classified as having
active or resolved infections, or as treatment experi-
enced or na€ıve, and were therefore excluded. Of the
remaining 458 (69.9%), the algorithm classified 163
(35.6%) individuals as treatment na€ıve, of whom 148
(90.8%) were listed as untreated in the Trent database,
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and 295 (64.4%) as treatment experienced, of whom
283 (95.9%) were listed as treated in the Trent data-
base (Fig. 2). In this study population, the algorithm
therefore demonstrated a sensitivity and specificity of
95% and 93%, respectively (positive predictive value
[PPV]: 96%; negative predictive value [NPV]: 91%)
and a Cohen’s kappa score of agreement of 0.87.
The 15 individuals who were reported in the Trent
database as treatment experienced, but were classified
by the algorithm as treatment na€ıve, had an insuffi-
cient number of HCV RNA tests undertaken within a
390-day window period. After further checking against
the Trent database, all 15 individuals had a number of
HCV RNA tests results reported to the sentinel sur-
veillance system, but these were unable to be linked to
the patients because of insufficient identifiers.
Of the 12 individuals classified as treatment experi-
enced, but recorded in the Trent database as na€ıve, 2
were shown to have been treated outside Trent (and
therefore this information had not entered the Trent
database); 1 had spontaneously cleared their infection,
4 were confirmed through their hospital records as
never having been treated, and there was no additional
information available for the remaining 5.
In total, 239 (84.5%) individuals who were correctly
classified as treatment experienced had an outcome
recorded in the Trent database. All 141 (100.0%) indi-
viduals with a documented SVR and 91 (93.0%) of the
remaining 98 with no evidence of a treatment response
were correctly classified by the algorithm. Therefore, as
a result, in this study population, the algorithm demon-
strated a sensitivity and specificity of 100% and 93%
for identification of a successful outcome of therapy,
respectively (PPV, 95%; NPV, 100%) and a Cohen’s
kappa score of agreement of 0.97.
HCV RNA test results held within the sentinel sur-
veillance and the Trent database were reviewed to deter-
mine the likely cause of the seven discrepant results. In
all cases, individuals in the sentinel surveillance database
had a negative HCV RNA test result, which was likely
Table 1. Characteristics of All Individuals Treated for HCV, England 2002-2011
Treated
PCR Tested Active HCV Infection (%) Number (%)* aORy CI P Value
Sex
Female 31,615 23,091 (73.0) 4,898 (21.2) 0.99 0.95-1.03 0.590
Male 64,415 52,269 (81.1) 11,145 (21.3) 1 — —
Unknown 4,610 4,000 (86.8) 495 (12.4) 0.52 0.47-0.57 <0.001
Age
<15 482 373 (77.4) 136 (36.5) 2.15 1.74-2.66 <0.001
15-24 6,914 5,097 (73.7) 998 (19.6) 0.91 0.84-0.98 0.010
25-34 27,967 21,421 (76.6) 4,052 (18.9) 0.87 0.83-0.91 <0.001
35-44 32,481 25,545 (78.6) 5,401 (21.1) 1 — —
45-54 20,189 16,351 (81.0) 4,183 (25.6) 1.28 1.22-1.34 <0.001
55-64 7,023 5,786 (82.4) 1,395 (24.1) 1.19 1.11-1.27 <0.001
>65 3,542 2,909 (82.1) 341 (11.7) 0.49 0.43-0.55 <0.001
Unknown 2,042 1,878 (92.0) 32 (1.7) 0.06 0.04-0.09 <0.001
Ethnicity
White 72,202 56,936 (78.9) 12,943 (22.7) 1 — —
Asian or Asian British 9,539 7,848 (82.3) 2,684 (34.2) 1.78 1.69-1.87 <0.001
Black or black British 602 465 (77.2) 113 (24.3) 1.1 0.87-1.34 0.431
Mixed or other 1,530 1,241 (81.1) 367 (29.6) 1.42 1.25-1.61 <0.001
Unknown 16,767 12,870 (76.8) 431 (3.3) 0.11 0.11-0.13 <0.001
Genotype
1 18,654 18,548 (99.4) 5,460 (29.4) 1 — —
2 2,698 2,664 (98.7) 826 (31.0) 1.07 0.98-1.17 0.130
3 19,218 19,030 (99.0) 5,835 (30.7) 1.06 1.01-1.11 0.011
4 1,321 1,313 (99.4) 475 (36.2) 1.37 1.22-1.54 <0.001
5 96 95 (99.0) 17 (17.9) 0.52 0.29-0.86 0.020
6 51 51 (100.0) 16 (31.4) 1.03 0.54-1.84 0.932
Unknown 58,602 37,659 (64.3) 3,909 (10.4) 0.28 0.26-0.29 <0.001
Grouped genotype
1 18,654 18,548 (99.4) 5,460 (29.4) 1 — —
Non-1 23,384 23,153 (99.0) 7,169 (31.0) 1.1 1.09-0.14 0.001
Unknown 58,602 37,659 (64.3) 3,909 (10.4) 0.23 0.22-0.24 <0.001
Total 100,640 79,360 (78.9) 16,538 (20.8) — — —
*Number of individuals treated, proportion of those with an active infection.
†Odds ratios adjusted for age group, sex, ethnicity, and genotype.
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to have been erroneously linked to that individual as a
result of partially missing personally identifiable infor-
mation and commonly occurring soundex codes.
Discussion
Data from laboratory information systems, collected as
part of a sentinel surveillance program, are a rich and val-
uable information resource. These data have provided
unique insights into changing testing practices, provided
context for the interpretation of routine laboratory
reports, and, for the first time, have enabled a country-
wide analysis of treatment among HCV-infected individu-
als using a method that has been demonstrated to be
robust. Here, we examined over 250,000 HCV RNA test
results, among 100,809 individuals, of whom approxi-
mately four in five had an active infection, with only one
in five having received antiviral therapy between 2002
and 2011. The number of individuals being treated in
the catchment of the sentinel laboratories annually
increased rapidly from under 500 in 2002 to well over
3,000 by 2008, but a more modest increase to 3,295 in
2009 and a decline to 3,110 by 2010. Even by 2010, not
all individuals with an active infection were treated, and
the majority of those who were treated had started ther-
apy within 2 years of their first HCV RNA.
Similar trends in the estimated number of individuals
treated for HCV in England have been reported using
prescribing and drug sales.15 These show a similar trend
with an increase in the numbers of people being treated
from approximately 3,000 in 2006 to approximately
5,000 in 2008/2009 and then a plateau, with a poten-
tial fall in the overall numbers being treated in 2010/
2011. Similar approaches using drug marketing data to
estimate treatment uptake have been used for compari-
son across Europe, with the UK ranking below other
European Union countries in the number of patients
treated.18 Elsewhere in the UK, the number of people
initiating therapy through HCV clinics in Scotland
increased from 468 to 1,049 between 2007/2008 and
2010/2011,19 after the launch of the Scotland Hepatitis
C Action Plan in 2006. Our data suggest that treatment
in England increased to a similar extent after the 2004
Hepatitis C Action Plan for England.20
Differences in treatment rates between countries may
reflect differences in overall prevalence or between expo-
sure groups and their respective access to services. Stud-
ies exploring patient-level factors associated with
treatment rates are therefore important.21-23 These stud-
ies provide a better understanding of barriers to treat-
ment and on where to direct resources. However,
analysis of factors associated with treatment and
response are limited to those routinely collected through
laboratory information systems and not the wider deter-
minants of the offer and uptake of treatment.
Using sequential HCV RNA test results from senti-
nel laboratories across England will be an underesti-
mate of those on treatment in England, but the
method allows us to discern temporal trends using
Fig. 1. Estimated number and HCV genotype of individuals starting treatment each year in England between 2002 and 2010. Estimates rely
on repeat PCR testing with a 390-day window period. Those tested later in the study period may have had a reduced opportunity of being
detected as on treatment. This is particularly the case for those with a first PCR test result in 2011. The data for 2011 are therefore not plotted,
but are included in the analysis of factors associated with treatment and response.
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routinely available data, with the benefit of being able
to explore individual-level characteristics in the future.
Furthermore, with European and U.S. hepatitis treat-
ment guidance recommending similar patterns of
HCV RNA testing during therapy,24,25 this method
could be employed more widely to obtain comparable
data.
The standard of care for patients with HCV in the
UK during this period of study was combination ther-
apy with pegylated interferon (Peg-IFN) and ribavirin
(RBV). These drugs, administered for either 48 weeks
for those with a genotype 1 or for 24 weeks for those
with non–genotype 1 infections, typically result in
SVR rates of 40%-50% and 80%, respectively.26 We
observed plausible SVR rates of approximately 55%
among those with a genotype 1 virus and 67% among
those with a non–genotype 1 virus. Therefore, routine
laboratory data may also provide an approach by
which response rates and patient-level factors can be
explored. Over the coming years, with the introduc-
tion of new direct-acting antiviral (DAA) agents, the
standard of care and virological monitoring of patients
with chronic HCV infection will dramatically change.
These new therapies and accompanying clinical guide-
lines will encompass more frequent and earlier HCV
RNA testing, which should make these individuals eas-
ier to identify using the algorithm described here.
Stratifying the number of individuals starting treatment
each year by genotype suggests a relative reluctance to
treat individuals with genotype 1 virus on the regimens
recommended in 2006.13 This reluctance may reflect the
poorer response rates26 and/or a desire to wait for the new
DAA agents. In 2012, these new agents (telaprevir and
boceprevir) were recommended by the National Institute
for Health and Clinical Excellence (NICE) for the treat-
ment of previously untreated adults with compensated
liver disease resulting from genotype 1 infection. This
may result in increasing treatment numbers among
patients with genotype 1 infection in the future.
Higher rates of treatment uptake among those under
15 years of age may reflect more frequent HCV RNA
testing among this group not because they are on therapy,
but as part of routine monitoring to better understand
Table 2. Characteristics of All Individuals Treated for HCV
Achieving an SVR, England 2002-2011
Treatment Response
Number (%)* aORy CI P Value
Sex
Female 3,197 (65.3) 1.12 1.05-1.20 0.002
Male 6,978 (62.6) 1 — —
Unknown 293 (59.2) 0.86 0.72-1.04 0.125
Age
<15 54 (39.7) 0.35 0.24-0.49 <0.001
15-24 647 (64.8) 0.97 0.84-1.12 0.693
25-34 2,671 (65.9) 1.02 0.94-1.11 0.660
35-44 3,537 (65.5) 1 — —
45-54 2,609 (62.4) 0.87 0.80-0.95 0.002
55-64 770 (55.2) 0.65 0.57-0.73 <0.001
>65 156 (45.7) 0.44 0.35-0.55 <0.001
Unknown 24 (75.0) 1.58 0.743.76 0.260
Ethnicity
White 8,157 (63.0) 1 — —
Asian or Asian British 1,789 (66.7) 1.17 1.07-1.28 <0.001
Black or black British 66 (58.4) 0.84 0.57-1.21 0.311
Mixed or other 227 (61.9) 0.95 0.77-1.18 0.640
Unknown 229 (53.1) 0.67 0.55-0.81 <0.001
Genotype
1 3,020 (55.3) 1 — —
2 572 (69.2) 1.81 1.55-2.13 <0.001
3 3,937 (67.5) 1.68 1.55-1.81 <0.001
4 278 (58.5) 1.14 0.94-1.38 0.176
5 11 (64.7) 1.48 0.56-4.31 0.440
6 14 (87.5) 5.66 1.58-36.04 0.022
Unknown 2,636 (67.4) 1.67 1.54-1.82 <0.001
Grouped genotype
1 3,020 (55.3) 1 — —
Non-1 4,812 (67.1) 1.65 1.54-1.78 <0.001
Unknown 2,636 (67.4) 1.67 1.53-1.82 <0.001
Total 10,468 (63.3) — — —
*Number of individuals achieving an SVR, proportion of those treated.
†Odds ratios adjusted for age group, sex, ethnicity, and genotype.
Fig. 2. Validation of treatment algorithm against the Trent HCV data-
base (DB). Treatment was attempted on individuals with no PCR test
result in the sentinel surveillance database because they may not
have had an active infection and therefore do not require treatment.
Because the algorithm relies on sequential PCR test results, they could
not have been appropriately classified.
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the natural history of infection in this patient group,
where there may be a significant possibility of spontane-
ous clearance at any age in childhood. Furthermore, poor
responses may reflect changes in drug licensing laws as
the European Medicines Agency did not approve the use
of Peg-IFN-a-2b and RBV until 2009, and NICE did
not publish draft guidance recommending Peg-IFN in
combination with RBV as an option for treating chronic
hepatitis C in children and young people until 2013.
Information on the reason for testing and risk factors
associated with HCV transmission is rarely recorded in
laboratory information systems. This limits further
exploration of the associations between genotype, eth-
nicity, treatment uptake, and outcome. As a result, it is
plausible that treatment rates and outcomes are dispro-
portionally affected by the overrepresentation of people
who inject drugs among those of white ethnicity.
Comparison with the Trent HCV cohort data dem-
onstrated that the algorithm based on testing patterns
was both highly sensitive and specific at both identify-
ing individuals on treatment, as well as treatment
outcome. A small number of individuals were misclassi-
fied as treatment experienced when they were not
(n5 12); however, these individuals had a clear pattern
of HCV RNA testing indistinguishable from those on
treatment. Some of these individuals were HCV RNA
tested through another laboratory contributing to the
sentinel surveillance database, suggesting that individuals
were being treated through a service not captured by
the Trent database. Conversely, the algorithm misclassi-
fied a small number of individuals (n5 15) as treat-
ment na€ıve. All of these individuals had an insufficient
number of HCV RNA test results identified within the
sentinel surveillance database, with wide inter-test inter-
vals. However, on further investigation, additional HCV
RNA test results were identified for these individuals in
the database, but were reported with insufficient patient
identifiers and therefore could not be reliably linked to
the individuals. Furthermore, the algorithm was able to
identify all individuals who achieved an SVR, but mis-
classified a small number of nonresponders. This high-
lighted an additional source of error where the result of
HCV RNA tests within the sentinel surveillance data-
base might be ascribed to the wrong individual because
of a lack of patient identifiers.
In England, the significant public health importance
of HCV and the need for an intensified response was
highlighted in the Hepatitis C Action Plan for Eng-
land.20 Among other things, the plan called for
improved surveillance activities and for high-quality serv-
ices for the testing, assessment, and treatment of all
patients with HCV. Surveillance and service delivery are
also likely to be key components of the imminent
National Liver Disease Outcomes Framework. However,
the recent changes to the NHS have reorganized and
redistributed commissioning and public health responsi-
bilities27 and have potential to result in disruption to
current HCV treatment pathways. We believe we have
identified a sensitive, robust, sustainable, and efficient
system to determine the effect of this transition and pro-
vide longer-term monitoring of treatment rates to drive
improved, equitable service provision across England.
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Vicca, Diana Princess of Wales Hospital, Grimsby; Julia
Locklan, Sheila Waugh, Freeman General Hospital,
Newcastle; Samreen Ijaz, Siew Lin Ngui, Richard Ted-
der, Sexually Transmitted and Blood Borne Virus Labo-
ratory, Health Protection Agency, Center for Infections,
London; Manoj Vallapil, Health Protection Agency,
Newcastle Laboratory, Newcastle General Hospital,
Newcastle; Elizabeth Boxall, Janet Mowbray, Health
Protection Agency West Midlands Laboratory, Heart of
England Foundation Trust, Birmingham; David Lewis,
Antony Hale, Leeds Teaching Hospitals NHS Trust,
Leeds; Ralph Henderson, David Johnson, Mark Zucker-
man, Kings College Hospital, London; Alan Blackley,
Paul Klapper, Manchester Medical Microbiology Part-
nership, Manchester Royal Infirmary, Manchester; Mat-
thew Longbone, Mohammed Osman Hassan Ibrahim,
Royal Sussex County Hospital, Brighton; Will Irving,
Lisa Prichett, Queens Medical Center, Nottingham; Jose-
phine Silles, HPA Collaborating Center, North Middlesex
University Hospital, London; Louise Hesketh, Microbiol-
ogy Laboratory, Royal Preston Hospital; Preston Lynne
Ashton, Ian Hart, Royal Liverpool Hospital, Liverpool;
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Tony Oliver, Xose Couto-Parada, Barts and The London
NHS Trust, London; Hasan Al-Ghusein, Phil Rice, St
George’s Hospital, London; Graham Hewitt, Gillian
Underhill; St Mary’s Hospital, Portsmouth; Mike Kidd,
Peter Luton, University College Hospital, London;
Mark Baker, James Nash, William Harvey Hospital,
Ashford, Kent.
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